Total Payments
$2,630
2024 Payments
$1,421
Companies
21
Transactions
131
Medicare Patients
604
Medicare Billing
$67,130
Payment Breakdown by Category
Food & Beverage$2,630 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,630 | 131 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $657.45 | 33 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $301.06 | 22 | $0 (2024) |
| Celgene Corporation | $209.67 | 24 | $0 (2024) |
| GENZYME CORPORATION | $201.51 | 8 | $0 (2024) |
| Gilead Sciences, Inc. | $186.84 | 4 | $0 (2023) |
| Phathom Pharmaceuticals, Inc. | $152.93 | 3 | $0 (2024) |
| QOL Medical, LLC | $139.69 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $124.78 | 1 | $0 (2023) |
| Ardelyx, Inc. | $102.31 | 6 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $93.19 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,421 | 65 | ABBVIE INC. ($418.26) |
| 2023 | $990.84 | 60 | AbbVie Inc. ($198.03) |
| 2022 | $55.92 | 3 | ABBVIE INC. ($41.16) |
| 2020 | $21.21 | 1 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($21.21) |
| 2019 | $125.00 | 1 | Gilead Sciences, Inc. ($125.00) |
| 2017 | $15.61 | 1 | PFIZER INC. ($15.61) |
All Payment Transactions
131 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/10/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $29.86 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.43 | General |
| Category: Gastroenterology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $31.32 | General |
| Category: Immunology | ||||||
| 12/05/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $27.69 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $1.05 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/19/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/18/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $13.62 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/13/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.49 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $1.32 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $17.29 | General |
| Category: GI | ||||||
| 10/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $0.68 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/27/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Immunology | ||||||
| 09/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $0.52 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $30.45 | General |
| Category: Immunology | ||||||
| 09/03/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $31.33 | General |
| Category: ENDOCRINOLOGY | ||||||
| 08/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: Immunology | ||||||
| 08/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 465 | 551 | $224,091 | $52,016 |
| 2022 | 9 | 139 | 167 | $62,676 | $15,114 |
Total Patients
604
Total Services
718
Medicare Billing
$67,130
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 54 | 56 | $46,025 | $11,124 | 24.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 68 | 71 | $30,530 | $5,601 | 18.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $18,676 | $5,516 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 53 | 82 | $21,286 | $5,350 | 25.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 80 | $19,196 | $4,982 | 26.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 36 | $15,728 | $4,622 | 29.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 45 | 45 | $14,237 | $3,414 | 24.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 45 | 45 | $28,611 | $3,034 | 10.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 28 | $6,390 | $2,614 | 40.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 28 | $10,280 | $2,434 | 23.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $6,094 | $1,530 | 25.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $4,848 | $1,247 | 25.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 11 | 11 | $2,190 | $549.59 | 25.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 39 | $8,853 | $2,226 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 21 | $8,736 | $2,189 | 25.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $8,216 | $2,064 | 25.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 22 | 22 | $8,074 | $2,015 | 25.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $6,540 | $1,635 | 25.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 19 | $6,194 | $1,558 | 25.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 12 | $5,184 | $1,300 | 25.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 14 | 15 | $6,735 | $1,091 | 16.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 14 | $4,144 | $1,036 | 25.0% |
About Dr. Jameel Shareef, DO
Dr. Jameel Shareef, DO is a Gastroenterology healthcare provider based in Warwick, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/18/2016. The National Provider Identifier (NPI) number assigned to this provider is 1891156824.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jameel Shareef, DO has received a total of $2,630 in payments from pharmaceutical and medical device companies, with $1,421 received in 2024. These payments were reported across 131 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($2,630).
As a Medicare-enrolled provider, Shareef has provided services to 604 Medicare beneficiaries, totaling 718 services with total Medicare billing of $67,130. Data is available for 2 years (2022–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Internal Medicine
- Location Warwick, RI
- Active Since 03/18/2016
- Last Updated 08/15/2023
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1891156824
Products in Payments
- ZEPOSIA (Drug) $334.45
- RINVOQ (Biological) $243.44
- DUPIXENT (Biological) $234.08
- ENTYVIO (Biological) $210.25
- CREON (Drug) $204.96
- VOQUEZNA (Drug) $152.93
- Vemlidy (Drug) $125.00
- SUCRAID (Drug) $110.33
- IBSRELA (Drug) $102.31
- LINZESS (Drug) $94.99
- XIFAXAN (Drug) $93.19
- TREMFYA (Drug) $74.24
- REBYOTA (Biological) $74.09
- GATTEX (Drug) $55.09
- VELSIPITY (Drug) $50.42
- VIBERZI (Drug) $41.70
- MAVYRET (Drug) $41.19
- Linzess (Drug) $39.16
- EOHILIA (Drug) $35.72
- VOWST (Biological) $34.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Warwick
Dr. Joseph Lowney, D.o, D.O
Gastroenterology — Payments: $242,134
Gastroenterology $242,134
Dr. Mohamed Azzouz, M.d, M.D
Gastroenterology — Payments: $4,416
Gastroenterology $4,416
Sulman Khan
Gastroenterology — Payments: $488.99
Gastroenterology $488.99
Timothy Graziano
Gastroenterology — Payments: $48.04
Gastroenterology $48.04
Jennette Butterfield, Npp, NPP
Gastroenterology
Gastroenterology
Mr. Antoine Hadamard, Md, MD
Gastroenterology
Gastroenterology